Moderna Strikes $1 Billion Deal to Develop mRNA Medicines Exclusively for China
- Moderna has signed agreements to research, develop, and manufacture mRNA medicines in China.
- The deal is worth around $1 billion and includes a memorandum of understanding and a land collaboration deal.
- Any drugs developed will be exclusively for use in China and will not be exported.
- Moderna's deal marks its first investment in China and expands the company beyond COVID-19 vaccines.
- Tensions are rising between the US and China, but China aims to become a leading biotech player.
CNN 
The Japan Times 
Boston Globe 
CNBC 
Reuters 
